Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy

Bibliography

• Bar RS, Peacock ML, Rechler MM, Receptors for multiplication-stimulating activity on human arterial and venous endothelial cells. J Clin Endocrinol Metab 1981;52:814-16
   Google Scholar
• Pollak MN, Perdue JF, Margolese RG, Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987;38:223-30
   PubMed Web of Science ®Google Scholar
• Liu JP, Baker J, Perkins AS, Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72
   PubMed Web of Science ®Google Scholar
• Mauro L, Salerno M, Morelli C, Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J Cell Physiol 2003;194:108-16
   PubMed Web of Science ®Google Scholar
• Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28:4985-95
   PubMed Web of Science ®Google Scholar
• Li YM, Schacher DH, Liu Q, Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 1997;138:362-8
   PubMedGoogle Scholar
• Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86
   PubMed Web of Science ®Google Scholar
• Oates AJ, Schumaker LM, Jenkins SB, The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998;47:269-81
   PubMed Web of Science ®Google Scholar
• Chappell SA, Walsh T, Walker RA, Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br J Cancer 1997;76:1558-61
   PubMedGoogle Scholar
• Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009;7:14
   PubMed Web of Science ®Google Scholar
• Chang Q, Li Y, White MF, Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 2002;62:6035-8
   PubMed Web of Science ®Google Scholar
• Liu YF, Paz K, Herschkovitz A, Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 2001;276:14459-65
   PubMed Web of Science ®Google Scholar
• Luzi L, Confalonieri S, Di Fiore PP, Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 2000;10:668-74
   PubMed Web of Science ®Google Scholar
• Chuderland D, Seger R. Protein–protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol 2005;29:57-74
   PubMed Web of Science ®Google Scholar
• Giorgetti S, Ballotti R, Kowalski-Chauvel A, The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem 1993;268:7358-64
   PubMedGoogle Scholar
• Moelling K, Schad K, Bosse M, Regulation of Raf-Akt cross-talk. J Biol Chem 2002;277:31099-106
   PubMedGoogle Scholar
• Peruzzi F, Prisco M, Dews M, Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-15
   PubMed Web of Science ®Google Scholar
• Singleton JR, Dixit VM, Feldman EL. Type 1 insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 1996;271:31791-4
   PubMed Web of Science ®Google Scholar
• Welsh GI, Miller CM, Loughlin AJ, Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 1998;421:125-30
   PubMed Web of Science ®Google Scholar
• Pap M, Cooper GM. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway. Mol Cell Biol 2002;22:578-86
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Watanabe Y, Miwa C, Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011;4:476-95
   PubMed Web of Science ®Google Scholar
• Shah OJ, Hunter T. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol 2006;26:6425-34
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Blouin MJ, Piura E, Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010;123:271-9
   PubMed Web of Science ®Google Scholar
• Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999;19:1346-58
   PubMed Web of Science ®Google Scholar
• Pene F, Claessens YE, Muller O, Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587-97
   PubMed Web of Science ®Google Scholar
• Wang J, Riedel H. Insulin-like growth factor-I receptor and insulin receptor association with a Src homology-2 domain-containing putative adapter. J Biol Chem 1998;273:3136-9
   PubMed Web of Science ®Google Scholar
• Duan C, Yang H, White MF, Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance. Mol Cell Biol 2004;24:7435-43
   PubMed Web of Science ®Google Scholar
• Yoshiga D, Sato N, Torisu T, Adaptor protein SH2-B linking receptor-tyrosine kinase and Akt promotes adipocyte differentiation by regulating peroxisome proliferator-activated receptor gamma messenger ribonucleic acid levels. Mol Endocrinol 2007;21:1120-31
   Google Scholar
• Stein EG, Gustafson TA, Hubbard SR. The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors. FEBS Lett 2001;493:106-11
   PubMed Web of Science ®Google Scholar
• Rajala RV, Chan MD. Identification of a NPXY motif in growth factor receptor-bound protein 14 (Grb14) and its interaction with the phosphotyrosine-binding (PTB) domain of IRS-1. Biochemistry 2005;44:7929-35
   Google Scholar
• Smith FM, Holt LJ, Garfield AS, Mice with a disruption of the imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during postnatal life. Mol Cell Biol 2007;27:5871-86
   PubMed Web of Science ®Google Scholar
• Huang Q, Szebenyi DM. Structural basis for the interaction between the growth factor-binding protein GRB10 and the E3 ubiquitin ligase NEDD4. J Biol Chem 2010;285:42130-9
   Google Scholar
• Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci 2003;94:1029-33
   PubMed Web of Science ®Google Scholar
• Haj FG, Verveer PJ, Squire A, Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 2002;295:1708-11
   PubMed Web of Science ®Google Scholar
• Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 2003;278:41677-84
   PubMedGoogle Scholar
• Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010;1:1170-7
   PubMedGoogle Scholar
• Sekharam M, Nasir A, Kaiser HE, Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res 2003;23(2B):1517-24
   Google Scholar
• Giorgetti-Peraldi S, Peyrade F, Baron V, Involvement of Janus kinases in the insulin signaling pathway. Eur J Biochem 1995;234:656-60
   Google Scholar
• Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008;27:1095-105
   PubMedGoogle Scholar
• Monno S, Newman MV, Cook M, Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells. Endocrinology 2000;141:544-50
   Google Scholar
• Del Valle L, Wang JY, Lassak A, Insulin-like growth factor I receptor signaling system in JC virus T antigen-induced primitive neuroectodermal tumors–medulloblastomas. J Neurovirol 2002;8(Suppl 2):138-47
   Google Scholar
• Tu X, Batta P, Innocent N, Nuclear translocation of insulin receptor substrate-1 by oncogenes and Igf-I. Effect on ribosomal RNA synthesis. J Biol Chem 2002;277:44357-65
   PubMed Web of Science ®Google Scholar
• Prisco M, Santini F, Baffa R, Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor. J Biol Chem 2002;277:32078-85
   PubMedGoogle Scholar
• Sisci D, Morelli C, Cascio S, The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann Oncol 2007;18(Suppl 6):vi81-5
   Google Scholar
• Lanzino M, Garofalo C, Morelli C, Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells. Breast Cancer Res Treat 2009;115:297-306
   PubMedGoogle Scholar
• Sisci D, Morelli C, Garofalo C, Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol 2007;60:633-41
   PubMed Web of Science ®Google Scholar
• Sun H, Tu X, Prisco M, Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol Endocrinol 2003;17:472-86
   PubMedGoogle Scholar
• Wu A, Chen J, Baserga R. Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 2008;27:397-403
   PubMedGoogle Scholar
• Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type 1 insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:485-98
   PubMed Web of Science ®Google Scholar
• Belfiore A, Frasca F, Pandini G, Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623
   PubMed Web of Science ®Google Scholar
• Knowlden JM, Hutcheson IR, Barrow D, Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609-18
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28
   PubMed Web of Science ®Google Scholar
• Tauszig-Delamasure S, Bouzas-Rodriguez J. Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy. Expert Opin Ther Targets 2011;15:847-58
   PubMed Web of Science ®Google Scholar
• Nikoletopoulou V, Lickert H, Frade JM, Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature 2010;467:59-63
   PubMed Web of Science ®Google Scholar
• Boucher J, Macotela Y, Bezy O, A kinase-independent role for unoccupied insulin and IGF-1 receptors in the control of apoptosis. Sci Signal 2010;3(151):ra87
   Google Scholar
• Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7
   PubMed Web of Science ®Google Scholar
• Jones RA, Campbell CI, Gunther EJ, Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26:1636-44
   PubMed Web of Science ®Google Scholar
• Berns EM, Klijn JG, van Staveren IL, Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 1992;52:1036-9
   PubMedGoogle Scholar
• Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 2005;9:753-68
   PubMed Web of Science ®Google Scholar
• Catalogue of somatic mutations in cancer. Cambridge, UK, Wellcome Trust Sanger Insitiute, 2011. Available from: http://www.sanger.ac.uk/genetics/CGP/cosmic/ [Last accessed 4 November 2011]
   Google Scholar
• Wan X, Harkavy B, Shen N, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40
   PubMed Web of Science ®Google Scholar
• Sachdev P, Jiang YX, Li W, Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J Biol Chem 2001;276:26461-71
   Google Scholar
• Wittrock J, Schweizer P, Girgert R. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. Anticancer Res 2002;22(6C):4205-9
   Google Scholar
• Mauro L, Bartucci M, Morelli C, IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem 2001;276:39892-7
   PubMed Web of Science ®Google Scholar
• Long L, Rubin R, Baserga R, Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995;55:1006-9
   PubMedGoogle Scholar
• Romano G, Prisco M, Zanocco-Marani T, Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J Cell Biochem 1999;72:294-310
   PubMed Web of Science ®Google Scholar
• Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000;19:5574-81
   PubMed Web of Science ®Google Scholar
• Surmacz E, Sell C, Swantek J, Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp Cell Res 1995;218:370-80
   PubMedGoogle Scholar
• Efstratiadis A. Genetics of mouse growth. Int J Dev Biol 1998;42:955-76
   PubMed Web of Science ®Google Scholar
• Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 1999;96:13180-5
   PubMed Web of Science ®Google Scholar
• Trumpp A, Refaeli Y, Oskarsson T, c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001;414:768-73
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Seeger RC, Schwab M, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4
   PubMed Web of Science ®Google Scholar
• Sell C, Dumenil G, Deveaud C, Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14:3604-12
   PubMed Web of Science ®Google Scholar
• Baker J, Liu JP, Robertson EJ, Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Kalebic T, Blakesley V, The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7
   PubMed Web of Science ®Google Scholar
• Wang W, Kumar P, Epstein J, Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 1998;58:4426-33
   PubMed Web of Science ®Google Scholar
• Liu JL, Blakesley VA, Gutkind JS, The constitutively active mutant Galpha13 transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor. J Biol Chem 1997;272:29438-41
   PubMed Web of Science ®Google Scholar
• Valentinis B, Morrione A, Taylor SJ, Insulin-like growth factor I receptor signaling in transformation by src oncogenes. Mol Cell Biol 1997;17:3744-54
   PubMedGoogle Scholar
• Sun H, Baserga R. The role of insulin receptor substrate-1 in transformation by v-src. J Cell Physiol 2008;215:725-32
   PubMedGoogle Scholar
• Baserga R. The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res 2009;315:727-32
   PubMedGoogle Scholar
• Tognon CE, Martin MJ, Moradian A, A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 2011; published online 1 August 2011; doi:10.1038/onc.2011.323
   Google Scholar
• Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995;55:249-52
   PubMed Web of Science ®Google Scholar
• Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37
   PubMed Web of Science ®Google Scholar
• Potratz JC, Saunders DN, Wai DH, Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 2010;70:8770-81
   Google Scholar
• Cao L, Yu Y, Darko I, Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-48
   PubMed Web of Science ®Google Scholar
• Morrison KB, Tognon C, Garnett MJ, ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene 2002;21:5684-95
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Benini S, Sarti M, Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4
   PubMed Web of Science ®Google Scholar
• Cironi L, Riggi N, Provero P, IGF1 is a common target gene of ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008;3:e2634
   PubMed Web of Science ®Google Scholar
• Karnieli E, Werner H, Rauscher FJ III, The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem 1996;271:19304-9
   PubMedGoogle Scholar
• Prieur A, Tirode F, Cohen P, EWS/FLI-1 silencing and gene profiling of ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83
   PubMed Web of Science ®Google Scholar
• Knezevich SR, McFadden DE, Tao W, A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18:184-7
   PubMed Web of Science ®Google Scholar
• Knezevich SR, Garnett MJ, Pysher TJ, ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998;58:5046-8
   PubMed Web of Science ®Google Scholar
• Tognon C, Garnett M, Kenward E, The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res 2001;61:8909-16
   PubMed Web of Science ®Google Scholar
• Martin MJ, Melnyk N, Pollard M, The insulin-like growth factor I receptor is required for akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 2006;26:1754-69
   PubMedGoogle Scholar
• Tognon CE, Somasiri AM, Evdokimova VE, ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res 2011;71:1060-70
   Google Scholar
• Dias P, Dilling M, Houghton P. The molecular basis of skeletal muscle differentiation. Semin Diagn Pathol 1994;11:3-14
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA, Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008;50:799-805
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Maris JM, Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; published online 31 May 2011; doi: 10.1002/pbc.23157
   Web of Science ®Google Scholar
• Kurzrock R, Patnaik A, Aisner J, A Phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010;16:2458-65
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sarantopoulos J, Patnaik A, Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7
   PubMed Web of Science ®Google Scholar
• Gualberto A. Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 2010;10:575-85
   PubMed Web of Science ®Google Scholar
• Yanochko GM, Eckhart W. Type 1 insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res 2006;8:R18
   PubMedGoogle Scholar
• Salatino M, Schillaci R, Proietti CJ, Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type 1 insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004;23:5161-74
   PubMed Web of Science ®Google Scholar
• Carboni JM, Lee AV, Hadsell DL, Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005;65:3781-7
   PubMed Web of Science ®Google Scholar
• Dunn SE, Ehrlich M, Sharp NJ, A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998;58:3353-61
   PubMed Web of Science ®Google Scholar
• Toniolo P, Bruning PF, Akhmedkhanov A, Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32
   PubMed Web of Science ®Google Scholar
• Tamimi RM, Colditz GA, Wang Y, Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011;128:243-50
   Google Scholar
• Resnik JL, Reichart DB, Huey K, Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998;58:1159-64
   PubMed Web of Science ®Google Scholar
• Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:423-9
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006;11:27-39
   PubMedGoogle Scholar
• Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002;8:BR521-6
   PubMedGoogle Scholar
• Haluska P, Carboni JM, TenEyck C, HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-98
   PubMed Web of Science ®Google Scholar
• Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008;68:1538-45
   PubMed Web of Science ®Google Scholar
• Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 2009;100:1-8
   PubMedGoogle Scholar
• Faivre S, Bouattour M, Raymond E. Novel molecular therapies in hepatocellular carcinoma. Liver Int 2011;31(Suppl 1):151-60
   Google Scholar
• Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1:1153-71
   PubMed Web of Science ®Google Scholar
• Berruti A, Ferrero A, Sperone P, Emerging drugs for adrenocortical carcinoma. Expert Opin Emerg Drugs 2008;13:497-509
   PubMed Web of Science ®Google Scholar
• Maulay V, Middleton MR, Eckhardt SG, Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. ASCO; 2010. J Clin Oncol 2010; p. 15s
   Google Scholar
• Haluska P, Worden F, Olmos D, Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-73
   PubMed Web of Science ®Google Scholar
• Samani AA, Yakar S, LeRoith D, The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47
   PubMed Web of Science ®Google Scholar
• Buck E, Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs 2011;20:605-21
   PubMed Web of Science ®Google Scholar
• Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010;16:2512-17
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28
   PubMed Web of Science ®Google Scholar
• Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials–early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83
   PubMed Web of Science ®Google Scholar
• Olmos D, Postel-Vinay S, Molife LR, Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase I expansion cohort study. Lancet Oncol 2010;11:129-35
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol 2010;11:105-6
   PubMed Web of Science ®Google Scholar
• Jassem J, Langer CJ, Karp DD, Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15 Suppl):abstr 7500
   Google Scholar
• Yap TA, Olmos D, Molife LR, Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs 2011;20:1293-304
   PubMed Web of Science ®Google Scholar
• Sachdev D, Singh R, Fujita-Yamaguchi Y, Down-regulation of insulin receptor by antibodies against the type 1 insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006;66:2391-402
   PubMed Web of Science ®Google Scholar
• Schenone S, Brullo C, Musumeci F, ATP-Competitive inhibitors of mTOR: an update. Curr Med Chem 2011;18:2995-3014
   PubMed Web of Science ®Google Scholar
• Martins AS, Ordonez JL, Garcia-Sanchez A, A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008;68:6260-70
   PubMed Web of Science ®Google Scholar
• Borinstein SC, Barkauskas DA, Krailo M, Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the children's oncology group. Cancer 2011;117:4966-76
   Google Scholar
• Yerushalmi R, Gelmon KA, Leung S, Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2011; published online 15 May 2011; doi: 10.1007/s10549-011-1529-8
   Google Scholar
• Bielen A, Perryman L, Box GM, Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRalpha/beta. Mol Cancer Ther 2011;10:1407-18
   PubMed Web of Science ®Google Scholar
• Zhang H, Pelzer AM, Kiang DT, Down-regulation of type 1 insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7
   PubMed Web of Science ®Google Scholar
• Ulanet DB, Ludwig DL, Kahn CR, Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010;107:10791-8
   PubMed Web of Science ®Google Scholar